The development of Alzheimer’s disease is linked to the presence of beta-amyloid plaques in the brain, which contributes to intracellular neurofibrillary tangles and disrupted cellular activities, leading to neurotoxin inflammation and neuronal death.
Detecting the presence of amyloid plaques has traditionally involved highly invasive techniques, often done postmortem. Studies from the past few years have found that optical imaging technology is able to detect the presence of amyloid plaques 15 to 20 years before a clinical diagnosis of Alzheimer’s Disease.
Beta-amyloid plaques can be seen in the retina years before it begins to accumulate in the brain. Neuro-Vision imaging technology is capable of differentiating between Alzhimer’s disease and non-Alzhimer’s disease with a high degree of statistical reliability (100% sensitivity and 81% specificity).